A FIRST! THE AQUALEG PROSTHESIS REFERENCED AND REIMBURSED BY THE FRENCH SOCIAL INSURANCE
The innovative prosthesis wraps created by Aqualeg, a member of the Atlanpole Biotherapies cluster, have been included in the list... View Article
Atlantic Bone Screen, a new website
Atlantic Bone Screen is pleased to present you its new website! New design, new content, new technology… it illustrates our... View Article
GE Healthcare and Valneva : new delivery for Vaccine Production
GE Healthcare and Valneva Collaboration Delivers Optimized Cell Culture Medium for Vaccine Production + Collaboration jointly developed a new medium optimized... View Article
Florence Hallouin is appointed Deputy Director of Atlanpole Biotherapies Cluster
Florence HALLOUIN is appointed Deputy Director of Atlanpole Biotherapies. She ensures the operational coordination of the Cluster, relationships with its partners... View Article
CESTI IHU: innovative strategies of tolerance induction in the transplanted patient
This research program, led by Dr. Sophie Conchon (CRTI – Inserm 1064 – ITUN) uses the specific immunological properties of... View Article
Affilogic signs with Takeda global pharma
Takeda and Affilogic entered into a research collaboration to develop therapies based on Nanofitines® in the central nervous system …... View Article
ARRONAX PLUS: NEW TOOLS TO ENRICH THE NUCLEAR ARSENAL AGAINST CANCER
The objective in nuclear medicine (imaging and therapy) is to build up both a world-class research group and eventually... View Article
BIOREGATE FORUM: A GREAT SUCCESS!
In September in Nantes, an International Forum dedicated to regenerative medicine was held, bringing together 180 participants. Based on the... View Article
Horama raises €4 million with Omnes Capital, Sham Innovation Santé and GO Capital
Horama raises €4 million with Omnes Capital, Sham Innovation Santé and GO Capital Proceeds from this fundraising will be used to:... View Article
OSE Immunotherapeutics : exercise of option within global license agreement with Janssen
OSE Immunotherapeutics announces exercise of option within global license agreement with Janssen for further clinical development of FR104 and potential commercialisation... View Article